Equities Analysts Issue Forecasts for Harrow FY2026 Earnings

Harrow, Inc. (NASDAQ:HROW - Free Report) - Equities research analysts at HC Wainwright issued their FY2026 earnings per share (EPS) estimates for shares of Harrow in a report issued on Monday, May 12th. HC Wainwright analyst Y. Chen anticipates that the company will post earnings of $0.40 per share for the year. HC Wainwright has a "Buy" rating and a $60.00 price target on the stock. The consensus estimate for Harrow's current full-year earnings is ($0.53) per share.

Harrow (NASDAQ:HROW - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.38) earnings per share for the quarter, missing analysts' consensus estimates of $0.02 by ($0.40). The firm had revenue of $47.83 million during the quarter, compared to analyst estimates of $57.00 million. Harrow had a negative return on equity of 45.57% and a negative net margin of 19.75%.

Separately, B. Riley dropped their price objective on Harrow from $69.00 to $65.00 and set a "buy" rating on the stock in a research note on Tuesday, April 1st.

Harrow Stock Down 1.5%

Harrow stock opened at $26.27 on Wednesday. The company has a debt-to-equity ratio of 3.23, a current ratio of 1.55 and a quick ratio of 1.44. Harrow has a fifty-two week low of $14.35 and a fifty-two week high of $59.23. The firm has a fifty day moving average price of $24.80 and a two-hundred day moving average price of $32.36. The firm has a market cap of $963.71 million, a price-to-earnings ratio of -27.95 and a beta of 0.41.

Hedge Funds Weigh In On Harrow

Institutional investors and hedge funds have recently bought and sold shares of the stock. GF Fund Management CO. LTD. bought a new stake in shares of Harrow in the 4th quarter worth approximately $25,000. Tower Research Capital LLC TRC boosted its holdings in Harrow by 769.5% during the fourth quarter. Tower Research Capital LLC TRC now owns 1,652 shares of the company's stock valued at $55,000 after purchasing an additional 1,462 shares in the last quarter. Aquatic Capital Management LLC bought a new stake in shares of Harrow in the 4th quarter valued at approximately $78,000. AlphaQuest LLC grew its stake in shares of Harrow by 452.8% in the 4th quarter. AlphaQuest LLC now owns 3,527 shares of the company's stock valued at $118,000 after purchasing an additional 2,889 shares during the period. Finally, GAMMA Investing LLC raised its holdings in shares of Harrow by 2,401.2% in the 1st quarter. GAMMA Investing LLC now owns 6,278 shares of the company's stock worth $1,670,000 after buying an additional 6,027 shares in the last quarter. Institutional investors own 72.76% of the company's stock.

Harrow Company Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.